Category Endocrinology/Glandular Disorders
Seraxis Wins Maryland Stem Cell Research Fund Grant to Accelerate Development of Allogenetically Compatible Pancreatic Islet Replacement Therapy for Functional Cure of T1D
$400,000 award will support characterization and efficacy testing of preclinical SR-03 cell line as a part of IND development. Seraxis is taking meetings at the American Diabetes Association Annual Meeting in Orlando, June 21-24.
Read Press Release
Seraxis’ Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes
GMP-compliant manufacturing puts SR-02 on track to be industry’s second clinical-stage stem cell derived pancreatic islet transplant program.
The third-party auditor’s FDA six-system approach yielded no critical nor major observations of Seraxis’ quality system for the production of GMP-grade organs from pancreas-derived stem cells.
Dr. William Rust, CEO, will present further data on the development of SR-02 and follow-on immune-cloaked SR-03 on Monday, January 8 at 10:30 a.m. PST at Biotech Showcase in San Francisco.
UC San Diego Shiley Eye Institute & Graves' Disease & Thyroid Foundation to Host Patient Education Event
UC San Diego Shiley Eye Institute and the Graves' Disease & Thyroid Foundation will host a patient education event on Saturday, May 7th from 8:30 a.m. until 5:00 p.m. at Shiley Eye Institute, 9415 Campus Point Drive, La Jolla, CA 92093-0946. Confirmed Presenters: David B. Granet, MD (Ophthalmology); Don O. Kikkawa, MD (Ophthalmology); Bobby S. Korn, MD, PhD (Ophthalmology); Kevin Brumund, MD (Thyroid Surgery); Karen McCowen, MD (Endocrinology); and Farshad Moradi, MD, PhD (Nuclear Medicine).
Read Press Release